Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Ural
A Ugur
AU
Avcu
Ferit
F
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001847:Bone Diseases / Q000209:etiology* / Q000628:therapy*; D001842:Bone and Bones / Q000378:metabolism; D002453:Cell Cycle; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D009101:Multiple Myeloma / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D009985:Orthopedics; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D019275:Radiopharmaceuticals; D000077211:Zoledronic Acid